138 related articles for article (PubMed ID: 36653933)
1. On assessing survival benefit of immunotherapy using long-term restricted mean survival time.
Horiguchi M; Tian L; Uno H
Stat Med; 2023 Apr; 42(8):1139-1155. PubMed ID: 36653933
[TBL] [Abstract][Full Text] [Related]
2. Dynamic RMST curves for survival analysis in clinical trials.
Liao JJZ; Liu GF; Wu WC
BMC Med Res Methodol; 2020 Aug; 20(1):218. PubMed ID: 32854619
[TBL] [Abstract][Full Text] [Related]
3. Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer.
Liang F; Zhang S; Wang Q; Li W
Ann Oncol; 2018 May; 29(5):1320-1324. PubMed ID: 29788167
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.
Huang B; Kuan PF
Pharm Stat; 2018 May; 17(3):202-213. PubMed ID: 29282880
[TBL] [Abstract][Full Text] [Related]
5. A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time-to-event data in randomized clinical trials.
Horiguchi M; Cronin AM; Takeuchi M; Uno H
Stat Med; 2018 Jul; 37(15):2307-2320. PubMed ID: 29682762
[TBL] [Abstract][Full Text] [Related]
6. Window mean survival time.
Paukner M; Chappell R
Stat Med; 2021 Nov; 40(25):5521-5533. PubMed ID: 34258772
[TBL] [Abstract][Full Text] [Related]
7. Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.
Pak K; Uno H; Kim DH; Tian L; Kane RC; Takeuchi M; Fu H; Claggett B; Wei LJ
JAMA Oncol; 2017 Dec; 3(12):1692-1696. PubMed ID: 28975263
[TBL] [Abstract][Full Text] [Related]
8. Ratio and difference of average hazard with survival weight: New measures to quantify survival benefit of new therapy.
Uno H; Horiguchi M
Stat Med; 2023 Mar; 42(7):936-952. PubMed ID: 36604833
[TBL] [Abstract][Full Text] [Related]
9. Assessing surrogacy using restricted mean survival time ratio for overall survival in non-small cell lung cancer immunotherapy studies.
Pang H; Yang G; Ho JC; Leung TH; Shi Q; Hu C; Stinchcombe TE; Wang X
Chin Clin Oncol; 2022 Feb; 11(1):7. PubMed ID: 35255696
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity Analysis for Restricted Mean Survival Time When Survival Curves Have Divergent Tails.
Ueno K; Morita S
Ther Innov Regul Sci; 2023 May; 57(3):467-471. PubMed ID: 36596962
[TBL] [Abstract][Full Text] [Related]
11. On the empirical choice of the time window for restricted mean survival time.
Tian L; Jin H; Uno H; Lu Y; Huang B; Anderson KM; Wei LJ
Biometrics; 2020 Dec; 76(4):1157-1166. PubMed ID: 32061098
[TBL] [Abstract][Full Text] [Related]
12. Restricted mean survival time as a summary measure of time-to-event outcome.
Hasegawa T; Misawa S; Nakagawa S; Tanaka S; Tanase T; Ugai H; Wakana A; Yodo Y; Tsuchiya S; Suganami H;
Pharm Stat; 2020 Jul; 19(4):436-453. PubMed ID: 32072769
[TBL] [Abstract][Full Text] [Related]
13. Restricted mean survival time for interval-censored data.
Zhang C; Wu Y; Yin G
Stat Med; 2020 Nov; 39(26):3879-3895. PubMed ID: 32767503
[TBL] [Abstract][Full Text] [Related]
14. Performance of Restricted Mean Survival Time Based Methods and Traditional Survival Methods: An Application in an Oncological Data.
Huang Q; Tian C
Comput Math Methods Med; 2022; 2022():7264382. PubMed ID: 36619796
[TBL] [Abstract][Full Text] [Related]
15. [Application of restricted mean survival time in clinical follow-up study].
Yang ZJ; Lyu JJ; Hou YW; Chen Z
Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Feb; 40(2):247-250. PubMed ID: 30744281
[TBL] [Abstract][Full Text] [Related]
16. Assessing surrogacy using restricted mean survival time ratio for overall survival in liver cancer: a narrative review.
Leung TH; Ho JC; Wang X; Pang H
Chin Clin Oncol; 2023 Oct; 12(5):53. PubMed ID: 37817506
[TBL] [Abstract][Full Text] [Related]
17. Complex survival trial design by the product integration method.
Tang Y
Stat Med; 2022 Feb; 41(4):798-814. PubMed ID: 34908180
[TBL] [Abstract][Full Text] [Related]
18. Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time.
Rahmadian AP; Delos Santos S; Parshad S; Everest L; Cheung MC; Chan KK
J Natl Compr Canc Netw; 2020 Mar; 18(3):278-285. PubMed ID: 32135516
[TBL] [Abstract][Full Text] [Related]
19. Quantifying treatment differences in confirmatory trials under non-proportional hazards.
Jiménez JL
J Appl Stat; 2022; 49(2):466-484. PubMed ID: 35707213
[TBL] [Abstract][Full Text] [Related]
20. Analysis of dynamic restricted mean survival time based on pseudo-observations.
Yang Z; Zhang C; Hou Y; Chen Z
Biometrics; 2023 Dec; 79(4):3690-3700. PubMed ID: 37337620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
